KR20150039748A - Gip 수용체 활성을 나타내는 글루카곤의 유사체들 - Google Patents

Gip 수용체 활성을 나타내는 글루카곤의 유사체들 Download PDF

Info

Publication number
KR20150039748A
KR20150039748A KR20157001447A KR20157001447A KR20150039748A KR 20150039748 A KR20150039748 A KR 20150039748A KR 20157001447 A KR20157001447 A KR 20157001447A KR 20157001447 A KR20157001447 A KR 20157001447A KR 20150039748 A KR20150039748 A KR 20150039748A
Authority
KR
South Korea
Prior art keywords
amino acid
glucagon
peptide
seq
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR20157001447A
Other languages
English (en)
Korean (ko)
Inventor
리차드 디. 디마치
데이비드 엘. 스마일리
콘라드 에이치. 블레이처
에릭 에이. 키타스
Original Assignee
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션, 에프. 호프만-라 로슈 아게 filed Critical 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션
Publication of KR20150039748A publication Critical patent/KR20150039748A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR20157001447A 2012-06-21 2013-06-18 Gip 수용체 활성을 나타내는 글루카곤의 유사체들 Abandoned KR20150039748A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662874P 2012-06-21 2012-06-21
US61/662,874 2012-06-21
US201361787973P 2013-03-15 2013-03-15
US61/787,973 2013-03-15
PCT/US2013/046229 WO2013192130A1 (en) 2012-06-21 2013-06-18 Analogs of glucagon exhibiting gip receptor activity

Publications (1)

Publication Number Publication Date
KR20150039748A true KR20150039748A (ko) 2015-04-13

Family

ID=48692696

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157001447A Abandoned KR20150039748A (ko) 2012-06-21 2013-06-18 Gip 수용체 활성을 나타내는 글루카곤의 유사체들

Country Status (30)

Country Link
US (2) US9868772B2 (cg-RX-API-DMAC10.html)
EP (1) EP2864350B1 (cg-RX-API-DMAC10.html)
JP (1) JP6300239B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150039748A (cg-RX-API-DMAC10.html)
CN (1) CN104583233B (cg-RX-API-DMAC10.html)
AR (1) AR091478A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013277372B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014031671A2 (cg-RX-API-DMAC10.html)
CA (1) CA2877127A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014003421A1 (cg-RX-API-DMAC10.html)
CO (1) CO7170125A2 (cg-RX-API-DMAC10.html)
CR (1) CR20150015A (cg-RX-API-DMAC10.html)
DK (1) DK2864350T3 (cg-RX-API-DMAC10.html)
EA (1) EA029025B1 (cg-RX-API-DMAC10.html)
ES (1) ES2674946T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20180936T1 (cg-RX-API-DMAC10.html)
HU (1) HUE039267T2 (cg-RX-API-DMAC10.html)
IL (1) IL236386B (cg-RX-API-DMAC10.html)
MX (1) MX356000B (cg-RX-API-DMAC10.html)
MY (1) MY185217A (cg-RX-API-DMAC10.html)
PE (1) PE20150863A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014502857A1 (cg-RX-API-DMAC10.html)
PL (1) PL2864350T3 (cg-RX-API-DMAC10.html)
PT (1) PT2864350T (cg-RX-API-DMAC10.html)
RS (1) RS57347B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201408491SA (cg-RX-API-DMAC10.html)
SI (1) SI2864350T1 (cg-RX-API-DMAC10.html)
TR (1) TR201808818T4 (cg-RX-API-DMAC10.html)
TW (1) TWI644920B (cg-RX-API-DMAC10.html)
WO (1) WO2013192130A1 (cg-RX-API-DMAC10.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2640916T3 (es) 2012-04-26 2017-11-07 Bristol-Myers Squibb Company Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activados por proteasa (PAR4) para tratar agregación plaquetaria
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
DK3004155T3 (da) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6581656B2 (ja) 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
KR102291020B1 (ko) 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
CN122440793A (zh) 2016-06-29 2026-07-24 韩美药品株式会社 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
CN115304666B (zh) * 2017-11-24 2025-09-19 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
SG11202010016QA (en) 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
PE20210473A1 (es) * 2018-05-04 2021-03-08 Novo Nordisk As Derivados de gip y usos de estos
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
ES3068975T3 (en) * 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
EP4112637A4 (en) * 2020-02-24 2024-04-03 Shenzhen Turier Biotech Co., Ltd. POLYPEPTIDE COMPOUND AND ITS APPLICATION IN THE PREVENTION OR TREATMENT OF DIABETES OR A COMPLICATION OF DIABETES
IL296592A (en) * 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
CN114621327B (zh) * 2020-12-10 2023-08-18 江苏中新医药有限公司 GLP-1、GIP和Gcg多重受体激动蛋白质
US20240059752A1 (en) 2020-12-23 2024-02-22 Zhejiang Doer Biologics Co., Ltd. Long-acting glucagon derivative
US20240174728A1 (en) * 2021-01-22 2024-05-30 Shenzhen Turier Biotech Co., Ltd. A use of a polypeptide compound in the preparation of drugs for preventing or treating inflammatory bowel diseases and related intestinal fibrosis
JP2024525843A (ja) * 2021-07-16 2024-07-12 ぺプ２タンゴ セラピューティクス インコーポレイテッド マルチアゴニストペプチドを含む組成物並びに製造及び使用方法
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法
JP7402574B1 (ja) * 2023-03-15 2023-12-21 株式会社合同資源 α－ヨード置換カルボン酸

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
IN165717B (cg-RX-API-DMAC10.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
NZ578948A (en) * 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
WO2010148089A1 (en) * 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
ES2661228T3 (es) * 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US8778872B2 (en) * 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN103857408B (zh) * 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
JP6184404B2 (ja) * 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物

Also Published As

Publication number Publication date
PT2864350T (pt) 2018-05-14
HRP20180936T1 (hr) 2018-12-14
MY185217A (en) 2021-04-30
SG11201408491SA (en) 2015-01-29
PH12014502857A1 (en) 2015-02-23
US9868772B2 (en) 2018-01-16
JP6300239B2 (ja) 2018-03-28
TR201808818T4 (tr) 2018-07-23
MX2014015556A (es) 2015-03-05
IL236386B (en) 2019-09-26
AR091478A1 (es) 2015-02-04
JP2015528795A (ja) 2015-10-01
PE20150863A1 (es) 2015-06-11
TWI644920B (zh) 2018-12-21
CL2014003421A1 (es) 2015-05-22
SI2864350T1 (en) 2018-08-31
HUE039267T2 (hu) 2018-12-28
US20150368310A1 (en) 2015-12-24
EA029025B1 (ru) 2018-01-31
PL2864350T3 (pl) 2019-01-31
CR20150015A (es) 2015-04-24
CA2877127A1 (en) 2013-12-27
EP2864350A1 (en) 2015-04-29
IL236386A0 (en) 2015-02-26
RS57347B1 (sr) 2018-08-31
AU2013277372A1 (en) 2014-12-11
TW201402603A (zh) 2014-01-16
WO2013192130A1 (en) 2013-12-27
MX356000B (es) 2018-05-08
ES2674946T3 (es) 2018-07-05
CN104583233B (zh) 2018-10-23
AU2013277372B2 (en) 2018-03-29
CO7170125A2 (es) 2015-01-28
BR112014031671A2 (pt) 2018-08-07
DK2864350T3 (en) 2018-05-28
US20180105569A1 (en) 2018-04-19
CN104583233A (zh) 2015-04-29
EA201590065A1 (ru) 2015-07-30
EP2864350B1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
EP2864350B1 (en) Analogs of glucagon exhibiting gip receptor activity
JP6086067B2 (ja) Ｇｉｐレセプター活性を示すグルカゴンアナローグ
JP6179864B2 (ja) グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
JP6311708B2 (ja) Ｇｉｐ受容体活性を示すグルカゴンアナローグ
US9487571B2 (en) Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
CN104945500B (zh) 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
HK1179856A (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
HK1153934B (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180611

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190924

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200325

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200813

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee